Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
AVITA Medical, Inc. reported first quarter and full-year 2024 results: revenue range of $14.8 to $15.6 million and $78.5 to $84.5 million. Guidance reaffirmed.
- Period
- first quarter and full-year 2024
- Revenue
- range of $14.8 to $15.6 million and $78.5 to $84.5 million
- Guidance
- reaffirmed
- Result
- guidance update
Exact text from the filing
committed to sustaining growth and building our business in 2024.” 2024 Financial Guidance • Commercial revenue for the first quarter 2024 is expected to be in the range of $14.8 to $15.6 million, reflecting growth at the lower bound of approximately 42% and upper bound of approximately 50% over the same period in the prior year • Commercial revenue for
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
AVITA Medical, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue approximately $14.1 million and approximately $49.8 million.
- Period
- fourth quarter and full-year ended December 31, 2023
- Revenue
- approximately $14.1 million and approximately $49.8 million
- Result
- preliminary results
Exact text from the filing
its post-market study, TONE. Preliminary Fourth Quarter and Full-Year 2023 Financial Highlights • Commercial revenue for the fourth quarter 2023 is expected to be approximately $14.1 million, an increase of approximately 50% compared to same period in 2022 • Commercial revenue for the full-year 2023 is expected to be approximately $49.8 million, an increase of
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
AVITA Medical, Inc. entered into Distribution Agreement with Stedical Scientific, Inc. valued at Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a (effective 2024-01-10).
- Action
- entry
- Agreement
- supply
- Counterparty
- Stedical Scientific, Inc.
- Value
- Exclusive distribution of PermeaDerm Biosynthetic Wound Matrix in the US; initial 5-year term with a
- Effective
- 2024-01-10
Exact text from the filing
On January 10, 2024, AVITA Medical Americas LLC (“AVITA Americas”), a wholly-owned subsidiary of AVITA Medical, Inc., (the “Company”) entered into an exclusive multi-year distribution agreement (“Agreement”) with Stedical Scientific, Inc. (“Stedical Scientific”) to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.
View on SEC.gov